Chimerix Inc. (CMRX) 3.71 $CMRX Chimerix to Participate

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Chimerix Inc. (CMRX) 3.71 $CMRX

Chimerix to Participate in Panel on North Carolina's Role in Biodefense Preparation at Medical, Biomedical and Biodefense Symposium
GlobeNewswire - Tue Jun 07, 7:00AM CDT
Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will participate in a panel focused on North Carolina's role in biodefense preparation at the "Medical, Biomedical and Biodefense: Support to the Warfighter Symposium" being held June 7-8, 2016 in Research Triangle Park, North Carolina.
CMRX: 3.71 (-0.08)

Premarket Research Report Covering the Biotech Industry
ACCESSWIRE - Mon Jun 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 6, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the biotech industry. Companies recently under review include Incyte, Chimerix, Lexicon Pharma, and Synthetic Biologics. Register with us now for your free membership and see our complete reports on these equities at:
SYN: 1.74 (-0.02), CMRX: 3.71 (-0.08), LXRX: 13.65 (-0.28), INCY: 80.02 (-1.64)

Bellicum Appoints Jim Daly to its Board of Directors
BusinessWire - Wed May 18, 6:00AM CDT
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Jim Daly to its Board of Directors. Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry and currently serves as a Director of ACADIA Pharmaceuticals, Halozyme Therapeutics, and Chimerix, Inc.
ACAD: 32.29 (-1.21), BLCM: 12.58 (-0.41), CMRX: 3.71 (-0.08)

Chimerix Announces Top-Line Interim AdVise Data and First Quarter 2016 Financial Results
GlobeNewswire - Mon May 09, 6:30AM CDT
- Maintains strong financial position with $314.5 million in capital at quarter end -
CMRX: 3.71 (-0.08)

Chimerix to Announce First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Tue May 03, 5:00PM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host a live conference call and audio webcast on Monday, May 9, 2016 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2016, and to provide a business overview.
CMRX: 3.71 (-0.08)

Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 16.98 (+0.08), CMRX: 3.71 (-0.08), GERN: 2.65 (-0.10), CYTX: 1.96 (-0.04), CLDX: 4.45 (-0.12), SGMO: 5.63 (-0.29), PTCT: 6.53 (-0.47), ATHX: 1.90 (-0.10), MNKD: 1.19 (-0.05)

Are These Biotech Stocks Worth your Attention? CELG, ARIA, EXEL, and CMRX
ACCESSWIRE - Tue Mar 22, 8:02AM CDT
NEW YORK, NY / ACCESSWIRE / March 22, 2016 / Despite the challenges that continue to press the Biotech industry, ValuableInvestment.com, this morning, turns its focus on the following Healthcare companies: Celgene Corp. (NASDAQ: CELG), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Exelixis Inc. (NASDAQ: EXEL), and Chimerix Inc. (NASDAQ: CMRX). Find out why these stocks are under our microscope by clicking the link below:
CMRX: 3.71 (-0.08), ARIA: 7.41 (-0.13), EXEL: 7.80 (-0.05), CELG: 98.07 (-2.59), CELGZ: 1.36 (-0.09)

Biotechs in the News
ACCESSWIRE - Mon Mar 21, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 21, 2016 / The past few weeks have been exciting for biotechnology stocks and this week see no difference. Several biotechs have disclosed news this week that has the market reacting favorably. Here are a few stocks you should take an immediate look at:
CPXX: 30.18 (+0.03), INO: 9.38 (-0.47), CMRX: 3.71 (-0.08), ORPN: 1.65 (-0.09), BLRX: 0.80 (-0.02)

Chimerix to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Wed Mar 09, 7:30AM CST
Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that Linda M. Richardson, Chief Commercial Officer of Chimerix, will present at the Barclays Global Healthcare Conference on Wednesday, March 16, 2016 at 2:35 p.m. ET at the Loews Miami Beach Hotel in Miami, FL.
CMRX: 3.71 (-0.08)

A Potential Answer To Antibiotic Resistance
ACCESSWIRE - Mon Mar 07, 12:22PM CST
NEW YORK, NY / ACCESSWIRE / March 7, 2016 / In a report modeled by Rand Europe and KPMG, and presented to the UK government at the end of 2014, analysts expect that by 2050, superbugs will kill more patients globally than cancer. Not something that is currently in the public consciousness, but a terrifying statistic nonetheless.
JNJ: 116.35 (-1.03), CMRX: 3.71 (-0.08), MRK: 56.47 (-1.21), CDTX: 10.49 (-0.41), GSK: 41.41 (-1.15)

Chimerix Announces Presentation of Detailed Results From Phase 3 SUPPRESS Trial at BMT Tandem Meetings
GlobeNewswire - Sat Feb 20, 8:15PM CST
Brincidofovir Shows On-Treatment Antiviral Effect in HCT Setting Despite Trial Not Meeting Primary Endpoint
CMRX: 3.70 (-0.09)

Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
GlobeNewswire - Mon Feb 08, 1:03PM CST
Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today presented positive results from a pivotal study of its antiviral, brincidofovir, in an animal model for smallpox at the ASM Biodefense and Emerging Diseases Research Meeting in Arlington, Virginia.
CMRX: 3.70 (-0.09)

Latest Global Chimerix, Inc. Market Research Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 5:12AM CST
'CHIMERIX, INC. - Product Pipeline Review - 2015', provides an overview of the CHIMERIX, INC.'s pharmaceutical research and development focus.
CMRX: 3.70 (-0.09)

WHO Declares Zika A Health Emergency of International Concern: 5 Companies Developing Technologies in the Fight against the Epidemic
ACCESSWIRE - Wed Feb 03, 8:22AM CST
WINDSOR, ON / ACCESSWIRE / February 3, 2016 / The Wealthy Biotech Trader (or "WBT" , an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, has researched several stocks on the front lines in the fight against Zika, an epidemic spreading from South America that causes flu-like symptoms but is feared to cause horrible birth defects in babies whose mothers become infected.
INO: 9.38 (-0.47), BCRX: 2.79 (-0.15), CMRX: 3.70 (-0.09), XON: 25.37 (+0.17)

Chimerix Inc. Is Roaring Higher Again -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jan 20, 2:54PM CST
What:  Investors in  Chimerix  managed to buck the market wide sell-off today as shares of the clinical-stage biopharma jumped more than 13% as of 2:50 p.m. ET after an analyst published a bullish forecast for the company's stock.  So what: ...
CMRX: 3.70 (-0.09), XBI: 53.09 (-1.43)

Strength Seen in Chimerix (CMRX): Stock Rises 8.1%
Zacks Equity Research - Zacks Investment Research - Wed Jan 20, 7:00AM CST
Chimerix (CMRX) was a big mover last session, with its shares rising just over 8% on the day.
CMRX: 3.70 (-0.09), ABAX: 46.22 (-0.89)

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/d53rgr/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus HHV-5 Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus HHV-5 Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cytomegalovirus HHV-5 Infections Overview - Therapeutics Development - Pipeline Products for Cytomegalovirus HHV-5 Infections - Overview - Pipeline Products for Cytomegalovirus HHV-5 Infections - Comparative Analysis - Cytomegalovirus HHV-5 Infections - Therapeutics under Development by Companies - Cytomegalovirus HHV-5 Infections - Therapeutics under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cytomegalovirus HHV-5 Infections - Products under Development by Companies - Cytomegalovirus HHV-5 Infections - Products under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Altor BioScience Corporation - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Atara Biotherapeutics, Inc. - Bionor Pharma ASA - Biotest AG - CAP-CMV GmbH - Cell Medica Limited - Chimerix, Inc. - China Biologic Products, Inc. - CyTuVax B.V. - GlaxoSmithKline Plc - Hookipa Biotech AG - Humabs BioMed SA - iQur Limited - Kadmon Corporation, LLC - Lead Discovery Center GmbH - Merck & Co., Inc. - Microbiotix, Inc. - Novartis AG - Pfizer Inc. - Phoenix Biotechnology, Inc. - Savoy Pharmaceuticals, Inc. - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - VBI Vaccines Inc. - Vical Incorporated For more information visit http://www.researchandmarkets.com/research/d5...egalovirus
CBPO: 102.47 (-3.67), VICL: 4.40 (-0.20), CMRX: 3.70 (-0.09), PFE: 34.11 (-0.48), MRK: 56.47 (-1.21), ATRA: 21.56 (-0.50), VBIV: 3.89 (-0.04), GSK: 41.41 (-1.15), NVS: 78.84 (-1.83)

4 Small Cap NASDAQ/NYSE Stocks That Are Trading with Heavy Volume Today
ACCESSWIRE - Tue Jan 19, 11:52AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / The Stock Expert is issuing a report on four stocks to watch. CMRX, AEZS, TMST and GBSN have been attracting the attention of major investors today. Continue reading to find out why.
GBSN: 1.88 (+0.14), TMST: 9.20 (-0.74), CMRX: 3.70 (-0.09), AEZS: 3.36 (-0.12)

Why Chimerix Inc. Is Up Big Today
Brian Feroldi, The Motley Fool - Motley Fool - Tue Jan 19, 11:50AM CST
What:  Shares of  Chimerix  , a clinical-stage biopharma focused on antiviral drugs, rose more than 13% as of 11:15 a.m. ET.  So what:  There doesn't appear to be any news today to justify the strong share price move, so it's likely that shares...
ESPR: 16.98 (+0.08), CMRX: 3.70 (-0.09)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 232

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 119

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 266

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 339

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 217

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 201

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 99

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 163

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Roku Inc. Shares Surge Following Strong Fiscal Report

Updated Category News Views 247

Roku Inc. Shows Resilience in Latest Earnings Report Roku, Inc. (NASDAQ: ROKU) has made headlines recently as its stock takes a positive turn following the release of its fourth-quarter results for the fiscal year 2024. The company's performance exceeded expectations, giving investors and analysts alike a reason to take notice. Strong Earnings Beat Analysts' Predictions...

Continue Reading
Cupshe Dominates Miami Swim Week with Unique Showcase

Updated Category News Views 145

Fashion Meets Storytelling at Miami Swim Week Well, it's official: Cupshe has shown up at Miami Swim Week 2026 with an offering that's turning heads. We're not just talking about another run-of-the-mill runway show. This edition, held at Temple House in Miami Beach, brought an immersive experience dubbed 'The Arrival'. They showcased 45 looks, making a statement with...

Continue Reading
AmeriServ Financial's New Contract Strengthens Workforce Relations

Updated Category News Views 136

AmeriServ Financial's New Labor Contract: A Positive Step Forward AmeriServ Financial Inc. (NASDAQ: ASRV) has successfully forged a new four-year labor contract with the United Steelworkers (USW) Local 2635-06. This recent agreement signifies a proactive approach to employee relationships, ensuring the bank remains a vital part of the community. Details of the Agreement...

Continue Reading
AS Tallink Grupp's Passenger and Cargo Transport Insights

Updated Category News Views 230

Overview of AS Tallink Grupp's May 2025 Performance In May 2025, AS Tallink Grupp reported the transportation of 472,683 passengers, reflecting a slight decline of 2.0% from the previous year. This decrease in passenger numbers is indicative of the ongoing challenges in the transportation sector. Along with passenger counts, the number of cargo units also saw a...

Continue Reading
B2B Food and Beverages E-commerce Market Insights for Future Growth

Updated Category News Views 248

The Expanding Landscape of B2B Food and Beverages E-commerce The B2B food and beverages e-commerce market is on an impressive trajectory, projected to ascend from USD 255.63 billion in 2024 to an astounding USD 1.15 trillion by 2034. This growth is fueled by an increasing demand for online transactions, ease of accessing supplies, and the innovation of diverse food and...

Continue Reading